Related Experiment Video
Updated: Jun 2, 2026
06:46
Ex Vivo Corneal Organ Culture Model for Wound Healing Studies
Published on: February 15, 2019
CCN2/decorin interactions: a novel approach to combating fibrosis?
1Department of Dentistry, University of Western Ontario, London, NGA 5C1, ON, Canada, Andrew.leask@schulich.uwo.ca.
Journal of Cell Communication and Signaling
|May 3, 2011
Summary
Decorin peptides can neutralize connective tissue growth factor (CCN2), a key driver of fibrosis. This discovery offers a promising new strategy for developing anti-fibrotic therapies.
Area of Science:
- Biochemistry
- Cell Biology
- Fibrosis Research
Background:
- Connective tissue growth factor (CCN2) is overexpressed in fibrotic diseases and crucial for fibrosis development.
- CCN2 mediates its effects through interactions with integrins and heparan sulfate-containing proteoglycans (HSPGs).
Purpose of the Study:
- To investigate decorin's potential to inhibit CCN2 activity.
- To explore the therapeutic potential of decorin-derived peptides as anti-fibrotic agents.
Main Methods:
- Investigated the binding interaction between decorin and CCN2.
- Utilized a peptide from the leucine-rich repeat region of decorin.
- Assessed the peptide's ability to neutralize CCN2 activity on C2C12 cells in vitro.
Main Results:
- Decorin was shown to bind CCN2.
- A specific decorin peptide (leucine-rich repeat peptide 12) effectively neutralized CCN2-mediated activity in vitro.
- This peptide demonstrated potential in blocking CCN2's fibrotic effects.
Conclusions:
- Decorin can directly bind and inhibit CCN2.
- Decorin-derived peptides represent a novel and potentially effective anti-fibrotic therapeutic strategy.
- Further research into CCN2-targeting peptides is warranted for fibrosis treatment.
